MarketInOut Stock Screener Log In | Sign Up

Altimmune Inc

IEX • Healthcare • Biotechnology • Quote as of 10/27/2026 15:59
Altimmune Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization392.93 mln
Float184 mln
Earnings Date11/10/2026

Piotroski F-Score

5 / 9
Neutral

Beneish M-Score

15.55
Highly suspicious

1-Year Forecast

17.11
Transformational upside

Relative Strength

7 / 100
Severely lagging

Debt / Equity

0.08
Debt-free

Pre-Tax Margin

-296,000%
Severely loss-making

Business Description

Altimmune is a medical research company working to bring new treatments to patients suffering from serious liver conditions. Its main drug in development, pemvidutide, targets two key biological pathways at once and is currently being tested in late-stage clinical trials for liver disease linked to metabolic dysfunction as well as alcohol-related conditions. Founded in 1997 and based in Gaithersburg, Maryland, the company is focused on advancing this treatment toward potential approval.

Key Fundamentals

EPS-0.76
ROE-34.49
RPS0.00
ROIC-229
ROA-29.57
Interest Cover-28.34
EBITDA, mln-88.12
EV / EBITDA-2.71
EV / EBIT-2.70
Revenue, mln0.03
EV / Revenue7,696

Quote Details

Last 2.04
Change -0.01 (-0.49%)
Open 2.07
Volume 3,966,884
Turnover 8,092,444
Average Volume 3,059,415

Financial Ratios

Pre-Tax Profit Margin-296,000
Leverage Ratio1.11
Current Ratio26.77
Price / Book1.17
Price / Tangible Book1.17
Debt / Equity0.08
Price / Sales12,675
PEG Ratio32.62

Financial Strength

Altman Z-Score4.88
Piotroski F-Score 5 / 9
Beneish M-Score15.55
1-Year Target Price17.11
Short Ratio11.98
Short % of Float23.72

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -11.3% 4 / 100   
1 Month -31.08% 5 / 100   
2 Months -27.4% 12 / 100   
6 Months -25.27% 17 / 100   
1 Year -48.35% 16 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog